This appeal challenged an interim order passed by a learned Single Judge which had restrained the appellants (Noviets Pharma) from using the mark ‘NOVIETS’ on the grounds of deceptive similarity and passing off against the respondents’ established mark ‘NOVARTIS’. A Division Bench of the Delhi High Court comprising Justice V. Kameswar Rao and Justice Manmeet Pritam Singh Arora dismissed the appeal, holding that the Single Judge exercised sound judicial discretion in protecting a well-known pharmaceutical mark, noting that both parties operate in overlapping medicinal and healthcare fields where public interest and consumer confusion are paramount.
- Prima Facie Deceptive Similarity: The Court affirmed that ‘Noviets’ is visually, phonetically, and structurally similar to ‘Novartis’, noting that replacing ‘AR’ with ‘IE’ does not create a sufficient distinguishing feature.
- Goodwill and Reputation: The respondents demonstrated substantial continuous use since 1996 alongside massive sales figures (e.g., INR 3,672 million in India for 2022-23), cementing ‘Novartis’ as a reputed, well-known trademark.
- Stricter Standard for Pharma Goods: Emphasizing public interest, the Bench reiterated that a stricter approach must be taken in pharmaceutical and healthcare trademarks to avoid life-threatening or harmful consumer confusion.
- Dishonest Adoption: The appellants failed to provide any plausible origin or explanation for adopting the coined term ‘Noviets’, pointing toward a dishonest intent to ride on the respondents’ goodwill.
- Limited Appellate Scope: Citing the classic principle from Wander Ltd. v. Antox India, the Court underscored that an appellate court will not interfere with a discretionary interlocutory order unless it is shown to be arbitrary, perverse, or contrary to law.
2026 DHC 6751
Noviets Pharma & Ors. v. Novartis AG & Ors. (D.O.J. 17.08.2026)




